title: [AUTOLOGOUS STEM CELL TRANSPLANTATION IN REFRACTORY OR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA - A SINGLE CENTRE EXPERIENCE].
abstract: Autologous stem cell transplantation represents the gold standard in chemosensitive diffuse B large cell lymphoma in relapse or in refractory setting. The aim of this study was to present the outcome of peripheral autologous stem cell transplantation in patients with refractory or relapsed diffuse large B cell lymphoma. We retrospectively analysed the data of 62 patients, who underwent this procedure for the period 2000-2013. The majority of patients (71%) were treated with miniBEAM salvage chemotherapy and all received BEAM myeloablative protocol followed by the stem cell reinfusion. The overall response rate for autologous transplantation was 75.8%. Median overall survival was 37.2 months. Median event-free survival was 16.9 months. Factors associated with overall survival were state of disease prior to salvage chemotherapy, chemosensitivity of disease, International prognostic index, disease activity at the relapse, response to autologous transplantation and post-transplantation radiotherapy. The use of rituximab was not significantly correlated to the outcome. In this patient group autologous stem cell transplantation was found to be effective in achieving remission and survival showing the adequate role of this procedure in this clinical setting. We stress out that autologous stem cell transplantation was effective in 32.5% patients with chemorefractory disease after salvage therapy.
authors.forename: Vibor
authors.initials: V
authors.lastname: Milunović
authors.forename: Martina Bogeljić
authors.initials: MB
authors.lastname: Patekar
authors.forename: Vinko
authors.initials: V
authors.lastname: Roso
authors.forename: Viktor
authors.initials: V
authors.lastname: Zatezalo
authors.forename: Bojana Aćamović
authors.initials: BA
authors.lastname: Stipinović
authors.forename: Karla Mišura
authors.initials: KM
authors.lastname: Jakobac
authors.forename: Njetočka Gredelj
authors.initials: NG
authors.lastname: Šimec
authors.forename: Delfa
authors.initials: D
authors.lastname: Radić-Krišto
authors.forename: Ana
authors.initials: A
authors.lastname: Planinc-Peraica
authors.forename: Slobodanka Ostojić
authors.initials: SO
authors.lastname: Kolonić
mesh_terms: D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D016896:Treatment Outcome